8.30 | Pre-Conference Virtual Networking

8.50 | Chair’s Opening Remarks

Reviewing the State of Play of the Inflammasome Therapeutics Space

9:00 am SWOT Analysis-Style Panel Discussion – Topics to be Addressed:

  • Paul Ashton President & CEO, Inflammasome Therapeutics, Inc.
  • Steve Glover Co-Founder, Chief Executive Officer & Chairman, Zyversa Therapeutics, Inc.
  • Anil K. Goyal CEO & Chairperson, IMMvention Therapeutix, Inc.


  • Reviewing the inflammasome therapeutics landscape – what have we learnt from recent progress and failures?
  • What are the strengths of inflammasome therapeutics that continue to drive their development in pharma and biotech pipelines?
  • What is the market opportunity and untapped clinical areas versus greatest unmet patient clinical need that can be addressed by emerging inflammasome therapeutics?
  • How have competing drug modalities reached late-stage clinical testing and what are the bottlenecks holding back inflammasome therapeutics from clinical success?

9:30 am Complementary Target Engagement and Functional Assays to Probe NLRP3 Pathway Antagonism


  • Three high throughput amenable, cell-based methods to support inflammasome drug discovery
  • NLRP3 inhibitors verified with multiplexed caspase-1 activity assay and IL-1β immunoassay
  • Live-cell NLRP3 BRET target engagement assay used to probe several NLRP3 inhibitors
  • Establish a relationship between the target binding and functional effects of NACHT domain inhibitors in live cells

10:00 am Scientific Poster Session

10:30 am Virtual Speed Networking & Break

Stream A – Understanding the Molecular Mechanisms of the Inflammasome
Chair: To Be Announced

Exploring Inflammasome Activation & Upstream Signalling to Identify Drug Targets

11:30 am Molecular Mechanisms of Inflammasome Regulation

  • Rebecca Coll Lecturer in Immunobiology & Principal Investigator, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast


  • What is ‘priming’ of the inflammasome?
  • Post-translational regulation of inflammasomes
  • Targeting priming and PTMs as therapeutic approaches for inflammasome mediated diseases

12:00 pm Discovering Brain Penetrant Therapeutics Targeting the NLRP3 Inflammasome Aimed to Address Unwanted Inflammatory Processes in Neurodegenerative Diseases


  • In neurodegenerative diseases, the misfolded proteins driving pathology, such as Abeta, Tau, alpha-synuclein and TDP-43, activate the NLRP3 inflammasome
  • Activating microglia and the NLRP3-ASC pathway in the brain drives inflammation, neuronal death and disease progression
  • Our approach is to target the NLRP3-ASC pathway to reduce neuroinflammation while preserving phagocytosis of the misfolded proteins

12:30 pm Mechanism of Inflammasome Signaling

  • Hao Wu Professor, Boston Children’s Hospital & Harvard Medical School


  • Inflammasome formation
  • Inflammasome trafficking
  • Inflammasome activation

Stream B – Advances in Pre-Clinical Models & Proof-of-Concept Trials
Gennaro Pagano
Expert Medical Director, Group Leader in Early Development

Validating Inflammasome Targets by Leveraging the Best Preclinical Tools in Your Toolbox

11:30 am BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation

  • Ashley Mansell Senior Director of Research & Development/Principal Investigator, Bacainn Therapeutics/Hudson Institute of Medical Research


  • BT032 is a novel first in class NLRP1 and NLRP3 inhibitor
  • BT032 directly targets NLRP1 and NLRP3 activity
  • BT032 reduces IAV-induced pulmonary inflammation in vivo

12:00 pm First-in-Class Allosteric Inhibitor of NEK7 to Block NLRP3 Inflammasome Assembly


  • Allosteric inhibition of NEK7 stops NLRP3 complexing
  • NLRP3 complexing can be reversed through NEK7 inhibition
  • Further, NEK7 inhibition initiates downstream changes in inflammatory signalling & suppresses pro-inflammatory cytokine propagation

12:30 pm Systemic Inflammatory Complications Following Traumatic Brain Injury


  • Traumatic Brain Injury (TBI) induces systemic inflammasome activation in lungs and heart
  • Systemic inflammasome activation is mediated by exosomes after TBI
  • IC100 is effective in blocking the systemic immune response after TBI

13.00 | Lunch Networking Break

2:00 pm Mitochondria as a Central Rheostat of NLRP3 Inflammasome Activation

  • Elsa Sanchez- Lopez Assistant Professor, University of California San Diego, Department of Orthopedic Surgery


  • Mitochondria can both activate and inhibit NLRP3 inflammasome activation
  • Mitochondria fitness is essential for mounting a proper NLRP3 inflammasome response
  • Targeting mitochondria can regulate NLRP3 inflammasome activity

2:30 pm Targeting the CARD8 Inflammasome for HIV Treatment & Cure

  • Liang Shan Assistant Professor, Washington University in St. Louis


  • The CARD8 inflammasome can detect HIV protease activity
  • Drugs that increase HIV protease activity or enhance CARD8 function, can drive pyroptosis of HIV-infected CD4+ T cells and macrophages

Leveraging Inflammasome Biomarkers in the Translational & Early Clinical Setting

2:00 pm Inflammasome Signaling After Traumatic Brain Injury: Mechanisms & Biomarkers

  • Juan Pablo de Rivero Vaccari Research Associate Professor of Neurological Surgery & The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine


  • Traumatic brain injury is an acute and chronic condition with pathophysiological events taking place from minutes to years after injury
  • The inflammasome plays an important role in the innate immune response after traumatic brain injury in rodents and humans
  • Inflammasome proteins are reliable biomarkers of traumatic brain injury

2:30 pm Use of NLRP3 Inflammasome Activity as a Disease Biomarker for Patient Stratification & the Design of Clinical Trials Testing NLRP3 Antagonists

  • Pablo Pelegrin Scientific Deputy Director, Biomedical Research Institute of Murcia University of Murcia


  • NLRP3 inflammasome response is able to early stratify septic patients gravity
  • A group of septic patients present a profound NLRP3 immunosuppression associated with their gravity
  • NLRP3 activity is as a biomarker to stratify patients and design clinical trials

15.00 | Afternoon Networking Break

Breakout Roundtable Discussions

4:00 pm Uncover the story behind leaps and setbacks from the movers and shakers of inflammasome research and drug development. Each roundtable will be hosted by an inflammasome R&D leader who will share a challenge, question, or case study to discuss:

1. Inflammasome Biomarkers & Evaluating the Best Methods to Accurately Quantify Inflammasome Proteins

2. Harnessing Public & Private Collaboration & Funding Opportunities to Accelerate Inflammasome Therapeutic R&D

4:45 pm Chair’s Closing Remarks

5:00 pm End of Conference Day One